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ex vivo modulation of the prostaglandin pathway in isolated 
progenitor cells may represent a novel and safe strategy to 
facilitate cell-based therapies.  Copyright © 2009 S. Karger AG, Basel
 Introduction
 A major goal in cardiovascular regenerative medicine 
is to halt or even reverse tissue damage by enhanced neo-
vascularization and regeneration. Endothelial progeni-
tor cells (EPC) play a crucial role in the functional bal-
ance of the vascular system as vascular function and 
neovascularization strongly depend on EPC number and 
functional capacity  [1, 2] . Since we have recently shown 
that progenitor cells isolated from patients with cardio-
vascular risk factors display a reduced neovasculariza-
tion capacity in vivo, novel strategies to enhance the 
functional activity of autologous progenitor cells are 
clearly warranted  [2, 3] . While several uncontrolled stud-
ies showed promising results for the intracoronary infu-
sion of adult stem and progenitor cells, more recent find-
ings from controlled studies showed mixed results with 
respect to efficacy  [4–7] . The inconclusive results from 
the 2 most recent randomized studies investigating the 
effect of treatment with bone marrow cells in patients 
following myocardial infarction  [6, 7] may be explained 
by methodological differences. However, considering 
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 Abstract
 Aims: The mobilization of endothelial progenitor cells (EPC) 
and their functioning in postnatal neovascularization are 
tightly regulated. To identify new modulators of EPC homeo-
stasis, we screened biologically active prostaglandin E com-
pounds for their effects on EPC production, trafficking and 
function.  Methods and Results: We found that EPC are a rich 
source for prostaglandin E 2  (PGE 2 ), stimulating their number 
and function in an auto- and paracrine manner. In vivo block-
ade of PGE 2  production by selective cyclooxygenase-2 inhi-
bition virtually abrogated ischemia-induced EPC mobiliza-
tion demonstrating its crucial role in EPC homeostasis 
following tissue ischemia. Conversely, ex vivo treatment of 
isolated EPC with the clinically approved PGE 1  analogue al-
prostadil enhanced EPC number and function. These effects 
were mediated by increased expression of the chemokine 
receptor CXCR4 and were dependent on nitric oxide syn-
thase activity. Most importantly, ex vivo PGE 1  pretreatment 
of isolated EPC significantly enhanced their neovasculariza-
tion capacity in a murine model of hind limb ischemia as 
 assessed by laser Doppler analysis, exercise stress test and 
immunohistochemistry.  Conclusions: The conserved role 
for PGE in the regulation of EPC homeostasis suggests that 
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that vascular disease often involves reduced numbers 
and/or function of progenitor cells, the results also 
strongly suggest that treatment effects of cell therapy us-
ing plain patient-derived autologous stem and progeni-
tor cells results in treatment effects that are not as strong 
as hoped for. Importantly, results from experimental 
studies using mostly healthy cells in a young and healthy 
environment may have been misleading in this respect.
 As we evaluated potential new candidates for ex vivo 
pretreatment of isolated autologous progenitor cells, 
prostaglandin E (PGE) captured our attention as a potent 
stimulator of endothelial progenitor cell number and 
function. Endogenous PGE 2  represents one of the major 
products of cyclooxygenase and has similar effects to the 
clinically approved analogue alprostadil via signaling 
through EP1, EP2, EP3 and EP4 receptors  [8, 9] . In the 
context of angiogenesis, EP2 and EP4 appear to be of par-
ticular importance. Both receptors are G s  coupled and 
increase intracellular cAMP formation in response to li-
gand binding, but they exert diverse downstream effects. 
While EP2 activation is known to enhance endothelial 
cell motility and survival via the Akt pathway  [10] , EP4 
activation leads to upregulation of VEGF, endothelial NO 
synthase (eNOS) and CXCR4 receptor expression via the 
PI3K and ERK 1/2 signalling pathways. It thus promotes 
cell migration, angiogenesis and homing  [11–14] .
 Here, we demonstrate that PGE 2  plays an essential role 
in EPC homeostasis. EPC depend critically on cyclooxy-
genase-2 (COX-2) activity, as EPC numbers were signifi-
cantly reduced by widely used COX-2 inhibitors. Most im-
portantly, we demonstrate for the first time the efficacy of 
these cells in the restitution of vasculature and function 
following ischemia. Regarding the translation of these 
findings into a clinical application, we provide evidence 
that ex vivo stimulation of the prostaglandin pathway in 
prospectively isolated EPC represents a novel and safe 
strategy to enhance the functional activity of autologous 
progenitor cells in patients with diverse vascular diseases.
 Subjects and Methods
 Recruitment of Study Patients and Healthy Control Subjects
 Peripheral blood was obtained from individuals after in-
formed consent had been given. Five male nondiabetics with an-
giographically documented stable coronary heart disease (mean 
age 64.0  8 4.5 years) were enrolled alongside 3 male age-matched 
diabetics without clinical evidence of coronary heart disease 
(mean age 43.7  8 21.5, known diabetes for 11.0  8 9.5 years, 
HbA1c 8.5  8 1.4%). Twenty healthy male control subjects were 
also enrolled (mean age 28.4  8 6.2 years).
 Human Progenitor Cell Isolation and Pretreatment
 Circulating endothelial progenitor cells were isolated from pe-
ripheral blood by density-gradient centrifugation with Ficoll, as 
previously described  [7, 12] . Briefly, total mononuclear cells (8  ! 
10 6  cells/ml medium, cell density 2.5  ! 10 6  cells/cm 2 ) were plated 
on plastic culture dishes coated with human fibronectin (Sigma, 
Munich, Germany) and maintained in endothelial basal medium 
supplemented with EGM SingleQuots (EBM, CellSystems, St. 
Katharinen, Germany), VEGF (100 ng/ml) and 20% fetal calf se-
rum (Biochrom, Berlin, Germany) for 96 h. Isolated cells were 
pretreated by exposure to the clinically approved PGE 1  analogue 
alprostadil (5 ng/ml; Sigma), the long-lasting derivate dmPGE 2
 (5 ng/ml; Cayman Chemical, Ann Arbor, Mich., USA), or one of 
the COX inhibitors aspirin (100   M ; Sigma), ibuprofen (100   M ; 
Sigma) and parecoxib (100   M ; Dynastat TM , Pfizer Inc., New York, 
N.Y., USA), during the final 24 h at 37  °  C with 5% CO 2 .
 Moreover, we also isolated endothelial colony-forming cells as 
an alternative source of progenitor cells, as previously described 
 [15] . Briefly, mononuclear cells were cultured with complete 
EGM-2 medium in 6-well tissue culture plates precoated with 
type 1 rat tail collagen (BD Biosciences, Bedford, Mass., USA). 
After 24 h, nonadherent cells and debris were removed. For the 
following 7 days, medium was changed daily, then every other day 
until the colonies appeared. Colonies were picked and further ex-
panded for the experiments.
 PGE 2  Levels in Supernatant
 After 24 h pretreatment, we determined PGE 2  levels in concen-
trated EPC-conditioned medium by ELISA according to the man-
ufacturer’s instructions (R&D Systems, Wiesbaden, Germany).
 Cell Cycle Analysis of Isolated Progenitor Cells
 To investigate proliferation and apoptosis, cells were analyzed 
using a BrdU Flow Kit (eBioscience, San Diego, Calif., USA). Cells 
were pulsed with BrdU for 2 h, and afterwards full cell cycle anal-
ysis was performed using BrdU and 7AAD from the kit. Experi-
ments were carried out according to the manufacturer’s instruc-
tions.
 eNOS mRNA Expression
 Total RNA from EPC was isolated by using the RNeasy kit 
(Qiagen, Hilden, Germany). RNA from HUVEC served as posi-
tive controls. Quantification of eNOS mRNA was performed by 
semiquantitative RT-PCR of 100 ng RNA and the previously de-
scribed primers  [16] .
 Assessment of the Migratory Capacity of Progenitor Cells
 A total of 5  ! 10 5  cells was resuspended in 250   l X-Vivo and 
placed in the upper chamber of a modified Boyden chamber filled 
with Matrigel TM  (BioCoat  invasion assay, 8   m pore size; BD 
Biosciences). For mechanistic analyses the eNOS inhibitor N G -
nitro- L -arginine-methyl-ester (LNMA; 1 m M ; Sigma Aldrich, St. 
Louis, Mo., USA) or CXCR4 neutralizing antibodies (20   g/ml; 
R&D Systems, Minneapolis, Minn., USA) were added. The upper 
chamber was placed in a 24-well culture   dish containing 500   l 
EBM supplemented with 100 ng/ml stromal-derived factor-1 (a 
specific CXCR4 ligand). After   24 h of incubation at 37  °  C, trans-
migrated cells were counted by 2 independent investigators. Sam-
ples were analyzed in duplicate.
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 Flow Cytometry
 Surface expression of endothelial markers and CXCR4 on hu-
man EPC was assessed by standard flow cytometry. Cells were 
incubated for 15 min with Flebogamma (Grifols, Langen, Ger-
many) to prevent unspecific binding of antibodies. Then, cells 
were stained using antibodies against CD31 (eBioscience) and 
CXCR4 (R&D Systems, Minneapolis, Minn., USA). We used flow 
cytometry analysis to identify murine EPC that stained double 
positive with FITC-conjugated antibodies against mouse CD34 
and PE-conjugated antibodies against Flk-1 (eBioscience). Stain-
ing was performed in the presence of saturating concentrations of 
rat monoclonal unconjugated antibodies against Fc receptors 
(anti-CD16/32; eBioscience) to prevent nonspecific binding. Iso-
type-identical antibodies served as controls (IgG 1 -PE and IgG 2a -
FITC; eBioscience). Each analysis included 100,000 gated events. 
All samples were analyzed using FACSCalibur and data were an-
alyzed with CELLQuest Pro software (both from Becton Dickin-
son, Franklin Lakes, N.J., USA).
 Animal Models
 All animal experiments were conducted in accordance with 
institutional guidelines and were approved by the administrative 
panel on laboratory animal care of the government of Upper Ba-
varia, Germany. 8- to 10-week-old female BALB/c WT mice and 
athymic NMRI nu/nu mice (both from Charles River, Sulzfeld, 
Germany) weighing 18–22 g were used in the experiments. For in 
vivo stimulation, BALB/c mice with or without hind limb isch-
emia were treated with 0.9% NaCl, PGE 2  analogue dmPGE 2  10 
  g/kg/day, or parecoxib 25 mg/kg/day intraperitoneally for 4 
days. NMRI nu/nu mice were subjected to hind limb ischemia
24 h before intravenous administration of pretreated human pro-
genitor cells (10 5  cells per mouse).
 Hind Limb Ischemia Model
 The in vivo neovascularization capacity of progenitor cells 
was investigated in a murine model of hind limb ischemia. The 
proximal portion of the right femoral artery, including the super-
ficial and the deep branches, were irreversibly disrupted by means 
of electrical coagulation. The overlying skin was closed using sur-
gical staples. 
 Limb Perfusion Measurements
 Two weeks after injection of the progenitor cells, we consecu-
tively determined the blood flow of the ischemic (right) and 
nonischemic (left) limb using the O2C laser Doppler blood flow 
analyzer and the micro probe LFM-2 (2 mm tissue penetration; 
both Lea Medizintechnik, Giessen, Germany). Prior to analysis, 
mice were placed on a heating pad at 37  °  C to minimize variations 
in temperature. Relative perfusion was calculated as the ratio of 
blood flow in the ischemic and the nonischemic limb. 
 Determination of the Exercise Capacity
 To assess alterations in the exercise capacity after progenitor 
cell infusion following hind limb ischemia, we performed swim-
ming tests using a countercurrent swimming pool  [23] . The cur-
rent in the pool was maintained at a flow rate of 1.0 m/s by means 
of 5 electric water pumps. The water temperature was maintained 
at 34  °  C by a water heater and thermostat. To accustom the mice 
to the swimming experience, all mice were subjected to daily 
swimming training for 7 consecutive days after which only mice 
with a stable maximum swimming time were selected for the 
study. The maximum swimming time was defined as the time to 
fail to remain above the surface of the water for more than 5 sec-
onds.
 Histological Analysis
 Capillary density was determined in 8-  m frozen sections of 
the adductor and semimembraneous muscles. Endothelial cells 
were stained for CD31 (PE-labeled; eBioscience). Myocyte mem-
branes were stained using an antibody to laminin (rabbit; Acris 
Antibodies GmbH, Hiddenhausen, Germany) followed by anti-
rabbit-Alexa 488 (Molecular Probes, Portland, Oreg., USA). Con-
ductance vessels in the adductor and semimembraneous muscles 
were identified by size ( 1 20   m) and staining of smooth muscle 
actin, using a Cy3-labeled mouse monoclonal antibody (Sigma). 
Small ( ! 50   m), medium (50–100   m) and large vessels ( 1 100 
  m) were counted separately. Injected human progenitor cells 
were identified by double staining for human HLA-ABC (APC-
labeled; eBioscience) and CD31 (FITC-labeled; eBioscience). Nu-
clei were stained with Dapi (Vector Lab, Burlingame, Calif., USA). 
Images were obtained by confocal microscopy (LSM 510 Meta; 
Zeiss, Germany).
 Isolation of Murine Spleen EPC
 Spleen progenitor cells were identified using the early EPC as-
say, as published previously  [18] . Briefly, spleens were placed in
2 ml of RPMI medium 1640 (Invitrogen, Carlsbad, Calif., USA) 
at 4  °  C. The tissue was minced and immediately homogenized and 
processed. Mononuclear cells were isolated by density gradient 
centrifugation using Ficoll (PAN Biotech, Aidenbach, Germany), 
washed and plated on fibronectin coated culture dishes. After 4 
days of EPC culture cell numbers were assessed by 2 independent 
investigators.
 Statistical Analysis
 If not stated otherwise, results for continuous variables are 
means  8 standard deviations and are illustrated as box plots (me-
dian, interquartile range, total range and outlier). Post hoc range 
tests and pairwise multiple comparisons were performed with the 
t test (2-sided) with Bonferroni adjustment. Comparison of cat-
egorical variables was generated by the Pearson   2  test. p  ! 0.05 
was considered statistically significant. All analyses were per-
formed with SPSS 12.0 (SPSS Inc., Chicago, Ill., USA).
 Results
 PGE 2  is an Endogenous Modulator of EPC 
Homeostasis
 To define the role of PGE 2  in EPC homeostasis, we de-
termined PGE 2  levels in concentrated EPC-conditioned 
medium by ELISA ( fig. 1 a). Treatment of isolated human 
EPC with clinically relevant doses of different COX in-
hibitors resulted in a marked reduction in PGE 2  levels. 
While aspirin, which primarily, but irreversibly, inhibits 
COX-1 demonstrated only a trend towards  reduced PGE 2  
levels, ibuprofen, a combined inhibitor of COX-1 and 
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COX-2, as well as the selective COX-2  inhibitor parecox-
ib significantly reduced PGE levels. Consistently, the 
number of cultured EPC was slightly, but not significant-
ly, reduced by aspirin ( fig. 1 b). In  contrast, ibuprofen 
treatment resulted in an almost 50% reduction of EPC 
numbers, an effect that could be  rescued by exogenous 
administration of PGE 2 . The  selective COX-2 inhibitor 
parecoxib reduced EPC numbers to an even greater ex-
tent (–70%). Notably, this effect could not be reversed by 
exogenous administration of PGE 2 . 
 Consistently, in vivo administration of PGE 2  in non-
ischemic mice resulted in a significant increase in the 
number of EPC in the bone marrow, spleen, and periph-
eral circulation ( fig. 1 c), whereas COX-2 inhibition did 
not alter EPC levels. To investigate the effect of COX-2 in-
hibition on ischemia-induced EPC mobilization, animals 
were subjected to hind limb ischemia. Strikingly, the isch-
emia-induced mobilization of EPC was virtually abrogat-
ed by selective COX-2 inhibition ( fig. 1 d). These data 
demonstrate a crucial role for PGE 2  in EPC homeostasis.
  C
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 Fig. 1. Role of endogenous PGE production on progenitor cell ho-
meostasis.  a PGE production in progenitor cell-conditioned medi-
um was assessed by ELISA. Human EPC were treated for 24 h with 
either vehicle, 5 ng/ml PGE 2 , or one of the following COX inhibitors 
at a concentration of 100   M . Aspirin blocks COX-1 irreversibly. 
Ibuprofen is an inhibitor of COX-1 and COX-2 and parecoxib selec-
tively inhibits COX-2.  b The effect of COX inhibition on progenitor 
cell numbers was investigated using the early EPC assay. Human 
cells were exposed to PGE 2  and/or the COX inhibitors during the 
final 24 h.  c The role of PGE 2  on progenitor cell homeostasis was 
investigated in vivo using nonischemic BALB/c mice. Mice intra-
peritoneally received 0.9% NaCl, PGE 2  analogue dmPGE 2 , or 
parecoxib. After 4 days of treatment, progenitor cells in bone mar-
row and peripheral blood were identified by flow cytometry follow-
ing staining for CD34 and VEGFR-2. Double positive cells were 
judged as endothelial progenitor cells. Spleen-derived EPC cells 
were identified using the early EPC assay.  d The role of endogenous 
PGE 2  in ischemia-induced progenitor cell mobilization was inves-
tigated using a murine model of hind limb ischemia. Treatment was 
started on the day of hind limb ischemia. 
104103102101100
100
101
102
103
104
Parecoxib
0.16%
CD34
FL2-H
104103102101100
100
101
102
103
104
V
EG
FR
-2
Control
1.54%
FL2-H
C
D
34
+
 V
EG
FR
-2
+
 E
PC
 in
 b
on
e 
m
ar
ro
w
 (%
)
n = 5
Control
n = 6
Parecoxib
n = 5
Control
n = 6
Parecoxib
n = 5
Control
n = 5
Parecoxib
0.5
1.0
1.5
2.0
2.5
3.0
3.5
0
1.0
2.0
3.0
4.0
0
0.1
0.2
0.3
C
D
34
+
 V
EG
FR
-2
+
 E
PC
 in
 p
er
ip
h
er
al
 b
lo
od
 (%
)
Sp
le
en
-d
er
iv
ed
 p
ro
g
en
it
or
 c
el
ls
 (%
)
* * *
* p < 0.05 
versus 
control
d
 Herrler/Leicht/Huber/Hermann/
Schwarz/Kopp/Heeschen
 
 J Vasc Res 2009;46:333–346   338
Pe
rc
en
ta
g
e 
of
 p
ro
lif
er
at
in
g
/a
p
op
to
ti
c 
EP
C
0
Proliferation Apoptosis
6
5
4
3
2
1
n =
 3
Co
nt
ro
l
n =
 3
PG
E1
 1
.0
n =
 3
PG
E1
 5
.0
*
*
* * p < 0.05 versus control
n =
 3
Co
nt
ro
l
n =
 3
PG
E1
 1
.0
n =
 3
PG
E1
 5
.0
Br
d
U
-F
IT
C
7AAD
0.38%
5.
55
%
Control
800 1,0006004002000
100
101
102
103
104
Br
d
U
-F
IT
C
7AAD
1.85%
2.
91
%
PGE1 1.0 ng/ml
800 1,0006004002000
100
101
102
103
104
Br
d
U
-F
IT
C
7AAD
5.39%
1.
58
%
PGE1 5.0 ng/ml
800 1,0006004002000
100
101
102
103
104
a
n =
 6
Co
nt
ro
l
n =
 7
PG
E 1 
5.0 n =
 5
Co
nt
ro
l
n =
 5
PG
E 1 
5.0 n =
 3
PG
E 1 
5.0n =
 3
Co
nt
ro
l
N
um
b
er
 o
f c
ul
tu
re
d
 e
ar
ly
 E
PC
(%
 o
f c
on
tr
ol
)
* p < 0.05 
versus 
control
Control
0.5
1.0
1.5
2.0
2.5
*
*
*
Dil-LDL
PGE1 5.0
Healthy
control
Nondiabetic
patients 
with CHD
Diabetics
without 
CHDb
 Fig. 2. Increase in cell proliferation, expression 
of CD31 and CXCR4 surface markers.  a Cell 
proliferation and apoptosis were assessed by 
flow cytometry using BrdU pulsing and 7AAD 
staining (upper panel). The PGE 1  analogue al-
prostadil was used for cell stimulation (lower 
left panel). Consistently, apoptosis was re-
duced upon pretreatment with PGE 1  (lower 
right panel).  b PGE 1  treatment resulted in in-
creased numbers of EPC. This effect was ob-
served both in cells from healthy controls as 
well as in cells derived from patients with cor-
onary heart disease (CHD) and diabetics, re-
spectively. 
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 Fig. 2. Increase in cell proliferation, expression of CD31 and 
CXCR4 surface markers.  c Expression of the endothelial marker 
CD31+ on EPC was determined by flow cytometry.  d eNOS ex-
pression was assessed by RT-PCR in progenitor cells after 4 days 
of treatment with increasing PGE 1  concentrations (n = 3).  e VEGF 
concentrations as assessed by ELISA in the supernatant were sig-
nificantly augmented in the presence of PGE 1 .  
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 Exogenous Administration of PGE 1  Increases Yield of 
Early EPC
 While PGE 2  is the predominant endogenous form of 
PGE, the PGE 1  analogue alprostadil has been approved for 
the treatment of peripheral artery disease and therefore 
was used for the subsequent translational experiments. In 
another set of experiments, we were able to demonstrate 
that in vivo stimulation of nonischemic mice is similarly 
effective with PGE 1  as compared to PGE 2  [change in blood 
borne EPC (% of control mice) for PGE 1  was 383  8 104% 
and for PGE 2  it was 350  8 180%; not significant]. More-
over, in this experimental setup, we did not find evidence 
for a strong proinflammatory effect during short-term 
treatment with either PGE 1  or PGE 2  [change in WBC (% 
control mice) for PGE 1  was 150  8 100% and for PGE 2  it 
was 130  8 30%; not significant]. Exposure of EPC to PGE 1  
for 4 days increased the number and proliferation of iso-
lated EPC. While a low PGE 1  dose of 1 ng/ml only slight - 
ly stimulated cell proliferation, 5 ng/ml PGE 1  caused al-
most 5% of the cells to proliferate compared to less than
1% in medium-treated control EPC ( fig. 2 a). Consistently, 
the number of apoptotic cells was reduced to around 1%
by high-dose PGE 1  treatment ( fig. 2 a). Consequently, the 
number of cultured early EPC in the PGE 1  group almost 
doubled as compared to control ( fig. 2 b). This treatment 
effect was also evident in EPC derived from patients with 
coronary heart disease and diabetics.
 Basal CD31 expression, a marker of endothelial differ-
entiation, is regularly low for early EPC, consistent with 
their status of emerging endothelial differentiation 
 ( fig. 2 c). Low-dose PGE 1  almost doubled CD31 expres-
sion as a marker of endothelial lineage, whereas 5 ng/ml 
yielded a 4-fold enhancement and led to robust CD31 ex-
pression in over 40% of cells, suggesting enhanced endo-
thelial differentiation. Moreover, ex vivo PGE 1  treatment 
significantly increased eNOS mRNA expression ( fig. 2 d). 
We also observed a 2.5-fold increase in VEGF concentra-
tions in EPC supernatant in the presence of high-dose 
PGE 1  ( fig. 2 e). This latter set of findings emphasizes the 
beneficial effects of PGE 1  on the functional activity of 
EPC by promoting their commitment to endothelial dif-
ferentiation rather than stemness characteristics.
 Importantly, we were able to reproduce the above data 
derived from EPC by using endothelial colony forming 
cells, which represent an EPC subpopulation with high 
proliferative capacity and strong regenerative capacity, 
through enhancing postnatal vasculogenesis  [15] . De-
spite their more differentiated nature with strong basal 
expression of the endothelial markers CD31 and VEGFR-
2, the stimulatory effect of PGE 1  on endothelial differen-
tiation was still evident (CD31 expression was 130% of 
control). Moreover, PGE 1  strongly induced proliferation 
of endothelial colony forming cells (BrdU for 2 h: 173% 
of control; apoptosis: 9.5% of control).
 Enhanced Functional Activity of Progenitor Cells by 
PGE 1 
 The CXCR4 receptor is critical for the migratory and 
homing capacity of circulating progenitors  [19] . CXCR4 
expression was significantly increased following PGE 1  
treatment ( fig. 3 a). Functionally, PGE 1  resulted in a sig-
nificant increase in the migratory activity ( fig. 3 b), while 
simultaneous treatment with neutralizing antibodies di-
rected against CXCR4 reduced the effect of PGE 1  on the 
migratory activity ( fig. 3 c). To define the role of eNOS in 
this enhanced functional activity, progenitor cells were 
simultaneously treated with the eNOS inhibitor LNMA, 
which significantly inhibited the effect of PGE 1  on migra-
tion. The simultaneous treatment of progenitor cells with 
LNMA and CXCR4 neutralizing antibodies completely 
abrogated the stimulatory effect of PGE 1  on cell migra-
tion. Thus, enhanced expression of eNOS and the chemo-
kine receptor CXCR4 critically mediates the effects of 
PGE 1  on the migratory activity of progenitor cells.
 Increased Neovascularization Capacity of Progenitor 
Cells after Pretreatment with PGE 1 
 To demonstrate the clinical applicability of our find-
ings, we investigated the neovascularization capacity of 
PGE 1 -pretreated human progenitor cells in a murine 
model of hind limb ischemia. The administration of pro-
genitor cells following ex vivo  PGE 1  pretreatment result-
ed in a significantly greater enhancement of limb perfu-
sion recovery as compared to the use of vehicle-treated 
progenitor cells ( fig. 4 a). Consistently, toe and foot necro-
sis in untreated animals (4/5) was markedly reduced to a 
single animal with toe necrosis in mice receiving PGE 1 -
pretreated progenitor cells. In order to illustrate that the 
enhanced recovery of ischemic hind limb perfusion is in-
deed associated with improved tissue function, the phys-
ical exercise capacity of the mice was assessed using a 
swimming test  [19] . Pretreatment of infused progenitor 
cells with PGE 1  significantly increased the swimming 
time ( fig. 4 b). 
 Correspondingly, the subsequent histological analysis 
of the adductor muscles by hematoxylin and eosin stain-
ing showed that the ischemic muscle was much better 
preserved in mice receiving PGE 1 -pretreated progenitor 
cells as compared to mice receiving untreated progenitor 
cells ( fig. 4 c). The capillary density in mice receiving 
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PGE 1 -treated progenitor cells was significantly higher as 
compared to vehicle-treated progenitor cells ( fig. 4 d). 
Furthermore, vascular incorporation and endothelial 
differentiation of injected progenitor cells was signifi-
cantly enhanced by pretreatment of infused progenitor 
cells with PGE 1  ( fig. 4 e).
 Discussion
 Based on our  in vitro and in vivo findings, the present 
study establishes PGE 2  as an endogenous regulator of 
EPC homeostasis. Importantly, we not only show that en-
dogenous PGE 2  modulates EPC numbers in vivo  in  re-
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sponse to tissue ischemia, but we also provide compelling 
evidence for the ex vivo enhancement of patient-derived 
EPC function by pretreatment with the PGE 1  analogue 
alprostadil prior to their potential use for autologous cell 
therapy. Although prostaglandin E has been primarily 
discussed in the context of inflammation, prostaglandins 
are known to be involved in multiple diverse physiologi-
cal and pathological processes. Their mode of action de-
pends on a variety of parameters (i.e. cell types involved, 
receptor expression profiles, and local prostaglandin 
concentrations)  [21, 22] . Indeed, the importance of pros-
taglandins in stem and progenitor cell development and 
function is just starting to emerge  [17, 23, 24] . Recent 
findings by North et al.  [23] uncovered a crucial role for 
PGE 2  in hematopoietic stem cell growth and develop-
ment in both embryonic and adult stem cell homeosta-
sis.
 We now demonstrate that COX-derived prostaglan-
dins also play an important role in human EPC homeo-
stasis. COX-1 is primarily important for the formation of 
the bone marrow niche  [23] , but COX-2 is clearly involved 
in the proliferation of EPC themselves. In contrast to the 
marginal reduction of EPC numbers following COX-1 in-
hibition, we found that selective COX-2 inhibition dra-
matically reduced EPC numbers, by about 70%, suggest-
ing that EPC possess a distinct regulatory machinery
predominantly depending on COX-2. Interestingly, the 
reduction in EPC numbers following selective COX-2 in-
hibition could not be reversed by exogenous administra-
tion of PGE 2 . These data suggest that the stimulatory ef-
fect on EPC is not primarily a direct pharmacological 
stimulation of the cells by PGE 2 , but rather an indirect 
effect of PGE 2  through enhanced expression of COX-2 
via the positive feedback loop of the PGE 2  COX-2 axis 
 [25] . Since COX-2 inhibition does not affect platelet func-
tion and expression of platelet aggregation markers  [26] , 
our data may at least in part explain the diverse cardio-
vascular risk profiles of aspirin and COX-2 inhibitors. 
While aspirin reduces cardiovascular risk, more recent 
evidence suggests that selective and nonselective COX-2 
inhibitors significantly increase cardiovascular event 
rates. Indeed, rather than causing an imbalance between 
COX-1-derived and COX-2-derived prostanoids, perma-
nent blockade of COX-2-dependent prostaglandins and 
consecutively reduced EPC numbers and function may at 
least in part explain the cardiovascular hazard conferred 
by selective COX-2 inhibitors  [27] and nonselective COX-
2 inhibitors such as ibuprofen and diclofenac  [28] . 
 Based on these data, new strategies aiming to modu-
late PGE signaling in isolated progenitor cells may have 
important clinical value to enhance the efficacy of au-
tologous cell therapy. Prior studies have documented 
that PGE 2  inhibits blood cell maturation in the mouse 
 [29, 30] and cell cycle stimulation in CFU-S8 progenitors 
 [31] . Gensch et al.  [32] recently showed a stimulatory ef-
fect for systemic PGE 1  administration on EPC mobiliza-
tion and subsequent neovascularization, effects exclu-
sively in a nonischemic murine model of inflammation-
induced neovascularization, while PGI 2  did not show 
any modulatory effect in the utilized system. However, 
data proving the in vivo relevance of PGE optimized hu-
man EPC in the regeneration of ischemic tissue are still 
lacking. Therefore, to determine the principles of func-
tional activity of short-lived PGE and to prove its benefi-
cial effect on human EPC, we have used the long-lasting 
PGE 2  derivate dmPGE 2  for our in vitro and in vivo stud-
ies  [23] . However, for the translation of our findings to 
clinically applicable autologous cell therapy, we sought a 
safe and approved drug with PGE 2 -like characteristics. 
Considering the PGE receptor binding properties of the 
PGE 1  analogue alprostadil, this drug indeed appeared to 
be the ideal candidate for our subsequent experiments. 
Intriguingly, in vitro pretreatment of human EPC with 
alprostadil markedly enhanced the culture yield and 
functional in vivo activity. These findings were indepen-
dent of whether EPC were derived from healthy donors 
or from patients with coronary heart disease and diabe-
tes, respectively. Considering the short half-life of PGE 1  
(5–10 min) and subsequently relatively low levels of cir-
culating PGE 1 , it is conceivable to assume that the in vi-
tro administration of PGE 1  bears greater therapeutic ef-
ficacy at lower financial burden as compared to system-
ic PGE 1  infusion. Indeed, the in vitro pretreatment of 
EPC provides the key advantage of avoiding systemic in-
travenous administration of PGE 1  with all its potential 
pro-inflammatory side effects for the patient rather than 
enabling the specific targeting of EPC for optimized cell 
therapy.
 We and others have reported that the contribution of 
progenitor cells to the formation of new vessels involves 
several crucial steps  [18, 19, 33–35] . Homing and trans-
migration represent the first steps which depend on 
CXCR4 expression and function  [36, 37] . Then, progeni-
tor cells have to undergo endothelial differentiation to 
physically participate in the formation of new vessels  [38] . 
The present experiments show that PGE 1  is capable of 
enhancing all of these processes. It increases CXCR4 ex-
pression and subsequently the transmigratory activity of 
the progenitor cells. Moreover, PGE 1  stimulates expres-
sion of genes associated with endothelial differentiation 
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including CD31, eNOS and VEGF, suggesting that PGE 1  
is also capable of enhancing endothelial commitment. 
Consistently, we observed in vivo a significantly en-
hanced vascular incorporation of the pretreated cells fol-
lowing hind limb ischemia. Therefore, our data demon-
strate that PGE 1  provides a multifactorial approach to 
considerably ameliorate neovascularization capacity of 
progenitor cells.
 As current clinical trials have not yet shown an en-
tirely satisfactory outcome following infusion of progen-
itor cells  [6, 7] , it appears crucial to develop adequate 
pretreatment modalities in order to achieve homing of 
the maximum possible contingent of progenitor cells to 
the targeted ischemic tissue, and, if possible, even aug-
ment their numbers prior to reinfusion. The present 
study demonstrates that pretreatment of progenitor cells 
with the PGE 1  analogue alprostadil is capable of enhanc-
ing the number and functional activity of these cells as 
well as reducing apoptosis by multimodal treatment ef-
fects, and this therefore represents a promising new ap-
proach for ex vivo pretreatment of patient-derived pro-
genitor cells. Our results could have major clinical impli-
cations as they introduce a feasible, cost-effective and 
safe pretreatment modality for isolated progenitor cells 
to enhance their therapeutic potential for autologous cell 
therapy in patients with acute or chronic cardiovascular 
diseases. 
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